- email:registrations@informa-ls.com
- phone:+44(0)20 7017 7481
 |
Immunotherapies and Cancer Vaccines
5 - 6 December 2012
|
Informa is launching our BRAND NEW Immunotherapies & Cancer Vaccines event this year. Reflecting on the increase in interest in cancer therapies and immunotherapeutic approaches to disease treatment, Informa bring you Europe's leading platform to bring both industry and academia together to discuss the latest cutting-edge research and developmental issues for immunotherapies
Europe's only conference dedicated to the latest industry updates in immunotherapy development
What does Immunotherapies & Cancer Vaccines 2012 offer you?
There has been a huge surge of interest and investment in cancer research over the last 10 years, which is still very much on the increase. One of the latest and most promising approaches to cancer therapy is immunotherapy, now viable due to the increased understanding of tumour immunology. Synthetic vaccines, immune modulators, immunotherapy antibodies and other agents have a forecasted market potential of $3 billion by 2015.
The FDA have recently approved two immunotherapeutic drugs which has sparked a new found interest in these technologies. There are estimated to be 150 potential drugs being studied, with around 60 in phase II/III.
Informa's event is Europe's leading Immunotherapy event looking into the latest scientific research driving these novel therapies, as well as providing the latest data from over 20 different companies giving insight into their therapeutic approaches and clinical trial design. For those professionals developing therapeutic vaccines for a variety of disease indications, this should be the confererence of choice in order to gain the latest insight into maximise your drug immune response, optimise clinical development and boost commercial success.
Dr Alan Korman, BMS presentation title confirmed
Antibody blockade of multiple negative T cell regulators (CTLA-4, PD-1, and LAG-3) contribute to anti-tumor responses
Presenting on Thursday 6th December, morning
Hear over 20 case studies from leading industry: BMS, Dendreon, Merck Serono, BN Immunotherapeutics, J&J and many more
Hear over 20 case studies from leading industry: BMS, Dendreon, Merck Serono, BN Immunotherapeutics, J&J and many more
Dr Harpreet Singh
Managing Director/CSO
Immatics Biotechnologies
|
Dr Emmanuelle Cornali
Head, Business Development
Aurigon Life Science
|
Professor Bernard Fox
Past President, SITC, Dept Molecular Microbiology and Immunology
OHSU
|
Dr Takashi Kei Kishimoto
Chief Scientific Officer
Selecta Biosciences
|
Dr Alan Korman
Vice President, Discovery Research
Bristol-Myers Squibb
|
Dr Michael Hanna
Founder & Chairman
Vaccinogen
|
Dr Reiner Haus
President, CEO
BN Immunotherapeutics
|
Dr Matthew Albert
Director, Research
Inserm
|
Additional speakers:
- Dr Michael G. Covington, CMC Senior Director, Regulatory Affairs, Dendreon, USA
- Dr Andrea van Elsas, Chief Scientific Officer, BioNovion, The Netherlands
- Dr Marc Mansour, CSO, Immunovaccine, Canada
- Dr Gary Wood, President and CEO, TVAX Biomedical, USA
- Dr Mary Antonysamy, VP of Preclinical and Translational Research, Biothera, USA
- Professor Ulrich Kalinke, Executive Director and Institute Director, Institute for Experimental Infection Research, TWINCORE, Centre of Experimental and Clinical Infection Research, Hannover Medical School, Germany
- Dr Takashi Kei Kishimoto, Chief Scientific Officer, Selecta Biosciences, USA
- Dr Charles A. Nicolette, Chief Scientific Officer, Vice President, Research and Development, Argos Therapeutics, Inc., USA
- Dr Emmanuelle Cornali, Head, Business Development, Aurigon Life Sciences, Germany
- Dr Cedrik M. Britten, Vice President R&D, Ribological GmbH, Germany
- Dr David Edwards, Non-Clinical Safety Manager, Cancer Research UK, UK
Sponsor
Spotlight Session Sponsor
Media Partners
Personalise your event by downloading our VIC Congress App NOW!
To download this app onto your computer click here, or via your mobile click here
Brand new Sponor announced: Immunospot
Informa are delighted to welcome C.T.L, Immunospot onto our Immunotherapies & Cancer Vaccines conference. Do not miss on Wednesday 5 December:
Challenges and Successes of Measuring Antigen-Specific T cell Responses
Dr Magdalena Tary-Lehmann, Chief Scientific Officer, Cellular Technology Limited (CTL), USA
Maximise your time out of the office by attending this additional seminar
Evening seminar: Wednesday 5 December: Practical Insight into Successful IND Applications
Led by: Dendreon, USA & Immunovative Therapies, Israel
With over 20 case studies from 20 of the leading pharma companies in the Immunotherapy field, this event offers the latest research and practical insight needed to drive your product process forward. What are the key topics covered this year?
***Global overview of the cancer vaccine field: Development issues, reimbursement, new direction & emerging markets***
*** Research driving immunotherapy improvement ***
*** Immunotherapy approaches: Active, passive, combination therapies ***
*** Preclinical trial rationale and assessment ***
*** Immune monitoring ***
*** Designing appropriate clinical trials ***
*** Novel delivery systems for immunotherapies ***
Other Events That Will Interest You
2nd Annual
Pre-Filled Syringes & Novel Injector Devices
17 Sep 2013 - 18 Sep 2013
Radisson Blu Hotel, Berlin, Germany
You Tube
Part of Informa's VIC Congress
Feeds | Like | Share    |
Alternative Language Options
Join our Immunotherapies and Cancer Vaccines LinkedIn group to network with industry and academic experts and discuss the latest research and development issues
Who should attend?
Seniority
- CEO, CSO, COO, CTO
- Senior/Directors
- Lab Heads
- Project Leaders
- Senior/Scientists
- Clinicians
Departments
- Immunology
- Clinical Development
- Translational Research
- Research & Devlopment
- Oncology
- Product development
- Lifecycle Management
- Commercialisation
- Regulatory
- Biology